← 產業報告目錄
Cell and gene Therapy Supply Chain Software Market Size, Share & Trends Analysis Report By Process Component (Sample Collection And Processing Components, Manufacturing Domains, Logistics Components, And Patient Identification And Treatment Follow-Up Components), Type Of Software, Mode Of Deployment, Type Of End-User, And Scale Of Operation, Region And Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-10頁數 180報告編號 INSIGHTACE-d3ebb2611b
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The Cell and gene Therapy Supply Chain Software Market on a global scale was estimated at USD 269.3 Mn in 2024 and is forecasted to attain USD 982.1 Mn by 2034, with a projected CAGR of 14.0% between 2025 and 2034.
The Cell and gene Therapy Supply Chain Software sector involves The recent commercial success of the cell and gene therapy market is to be seen due to their ability to provide the desired therapeutic benefits and developers' capacity to meet all supply chain needs. This domain has witnessed marked transformation owing to technological breakthroughs and shifting healthcare dynamics.
The market's upward path is driven by escalating healthcare spending, technological evolution, and the escalating focus on personalized and precision-based approaches in healthcare.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
From a regional perspective, mature markets in North America and Europe continue to hold marked shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and escalating investment in the sector.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cell and Gene Therapy Supply Chain Software Market Snapshot
Chapter 4. Global Cell and Gene Therapy Supply Chain Software Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Process Component Estimates & Trend Analysis
5.1. by Process Component & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Process Component:
5.2.1. Sample Collection and Processing Component
5.2.2. Manufacturing Component
5.2.3. Logistics Component
5.2.4. Patient Identification and Treatment Follow-up Component
Chapter 6. Market Segmentation 2: by Type of Software Estimates & Trend Analysis
6.1. by Type of Software & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Software:
6.2.1. Enterprise Manufacturing System (EMS)
6.2.2. Laboratory Information Management System (LIMS)
6.2.3. Inventory Management System (IMS)
6.2.4. Cell Orchestration Platform (COP)
6.2.5. Quality Management System (QMS)
6.2.6. Logistics Management System (LMS)
6.2.7. Patient Management System (PMS)
Chapter 7. Market Segmentation 3: by Mode of Deployment Estimates & Trend Analysis
7.1. by Mode of Deployment & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Mode of Deployment:
7.2.1. On-premises Deployment
7.2.2. Cloud-based Deployment
Chapter 8. Market Segmentation 4: by Scale of Operation Estimates & Trend Analysis
8.1. by Scale of Operation & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Scale of Operation:
8.2.1. Clinical Scale
8.2.2. Commercial Scale
Chapter 9. Market Segmentation 5: by End-User Estimates & Trend Analysis
9.1. by End-User & Market Share, 2024 & 2034
9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End-User:
9.2.1. Pharmaceutical Companies
9.2.2. Cell Therapy Labs
9.2.3. Hospitals / Medical Centers
9.2.4. Research Institutes / Biobanks
Chapter 10. Cell and Gene Therapy Supply Chain Software Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. North America
10.1.1. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Process Component,2021-2034
10.1.2. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Type of Software, 2021-2034
10.1.3. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Mode of Deployment, 2021-2034
10.1.4. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation,2021-2034
10.1.5. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.1.6. North America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.2. Europe
10.2.1. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Process Component, 2021-2034
10.2.2. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Type of Software, 2021-2034
10.2.3. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Mode of Deployment, 2021-2034
10.2.4. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation,2021-2034
10.2.5. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.2.6. Europe Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.3. Asia Pacific
10.3.1. Asia Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Process Component, 2021-2034
10.3.2. Asia Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Type of Software, 2021-2034
10.3.3. Asia-Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Mode of Deployment, 2021-2034
10.3.4. Asia Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation,2021-2034
10.3.5. Asia Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.3.6. Asia Pacific Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.4. Latin America
10.4.1. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Process Component, 2021-2034
10.4.2. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Type of Software, 2021-2034
10.4.3. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Mode of Deployment, 2021-2034
10.4.4. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation,2021-2034
10.4.5. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.4.6. Latin America Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.5. Middle East & Africa
10.5.1. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Process Component, 2021-2034
10.5.2. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Type of Software, 2021-2034
10.5.3. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Mode of Deployment, 2021-2034
10.5.4. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation,2021-2034
10.5.5. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.5.6. Middle East & Africa Cell and Gene Therapy Supply Chain Software Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Azenta Life Sciences
11.2.2. Biocair
11.2.3. BioLife Solutions
11.2.4. CareDx
11.2.5. Cryoport
11.2.6. Lonza
11.2.7. NMDP BioTherapies
11.2.8. TraceLink
11.2.9. TrakCel
11.2.10. Veeva Systems
11.2.11. Emerson
11.2.12. LabVantage Solutions
11.2.13. Marken
11.2.14. MasterControl
11.2.15. QuickSTAT
11.2.16. Siemens
11.2.17. Stafa Cellular Therapy
11.2.18. Steiner
11.2.19. STEMSOFT Software
11.2.20. TECHNIDATA
11.2.21. Thermo Fisher Scientific
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們